Tirzepatide

Overview

Tirzepatide (LY3298176) is a synthetic dual-agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Originally developed by Eli Lilly, it was the first dual incretin receptor agonist to reach clinical use. Extensive clinical trial data from the SURPASS and SURMOUNT programs have generated substantial research interest in its metabolic mechanisms. Its 39-amino-acid sequence is based on the native GIP sequence with modifications enabling GLP-1 receptor cross-reactivity.

Mechanism of Action

Tirzepatide binds with high affinity to the GIP receptor and with lower but clinically relevant affinity to the GLP-1 receptor. GIP receptor activation potentiates glucose-dependent insulin secretion from pancreatic beta cells and may influence adipose tissue lipid storage and energy expenditure. GLP-1 receptor activation suppresses glucagon release, delays gastric emptying, and activates central satiety pathways. A C20 fatty di-acid moiety enables albumin binding, extending the half-life to approximately 5 days.

Research Applications

• Dual-incretin receptor signalling research
• Glucose homeostasis and insulin secretion studies
• Body composition and adipose tissue research
• Gastric motility and appetite regulation models
• Comparative pharmacology with mono-agonists